Published in J Biomed Mater Res on October 01, 1998
Surface modification of silica nanoparticles to reduce aggregation and nonspecific binding. Langmuir (2006) 2.17
Drug transport to brain with targeted nanoparticles. NeuroRx (2005) 1.37
Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett (2012) 1.31
Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomedicine (2012) 1.10
Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI. Proc Natl Acad Sci U S A (2008) 0.93
Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine (2012) 0.92
Poly(lactic-co-glycolic) acid as a carrier for imaging contrast agents. Pharm Res (2008) 0.91
Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery. Int J Nanomedicine (2012) 0.89
Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob Agents Chemother (2004) 0.88
PEG-grafted chitosan nanoparticles as an injectable carrier for sustained protein release. J Mater Sci Mater Med (2008) 0.88
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Epidemiological basis for clinical diagnosis of childhood malaria in endemic zone in West Africa. Lancet (1991) 5.11
Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet (1999) 3.43
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Localization of the CHIP28 water channel in rat kidney. Am J Physiol (1992) 2.17
Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease - evidence from systematic reviews of randomized controlled trials (second update, January 2006). J Hum Nutr Diet (2006) 2.09
Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev (2001) 1.99
Nosocomial outbreak of multiple bloodborne viral infections. J Infect Dis (2001) 1.89
Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis (1994) 1.82
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS (2003) 1.76
Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release (2001) 1.73
Rapid and sensitive detection of enteroviruses in specimens from patients with aseptic meningitis. J Clin Microbiol (1996) 1.67
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol (1998) 1.65
Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.65
Emergence delirium in a child given oral midazolam for conscious sedation. Ann Emerg Med (1994) 1.63
Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res (1997) 1.58
Constitutive and regulated membrane expression of aquaporin 1 and aquaporin 2 water channels in stably transfected LLC-PK1 epithelial cells. Proc Natl Acad Sci U S A (1995) 1.54
The prevalence of Peyronie's disease: results of a large survey. BJU Int (2001) 1.51
Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis (1990) 1.50
Expression of aquaporin-4 in fast-twitch fibers of mammalian skeletal muscle. J Clin Invest (1998) 1.48
Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res (2001) 1.48
Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayered devices for buccal drug delivery. J Control Release (1998) 1.47
Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol (1996) 1.47
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS (1998) 1.46
Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials (2001) 1.46
Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS (2000) 1.44
The dental management of patients with natural rubber latex allergy. Br Dent J (1998) 1.44
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS (1999) 1.44
The AQP2 water channel: effect of vasopressin treatment, microtubule disruption, and distribution in neonatal rats. J Membr Biol (1995) 1.44
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm (2001) 1.42
[Post-exposure HIV prevention: eligibility of patients recently infected by sexual exposure]. Schweiz Med Wochenschr (1999) 1.40
Nutritional and metabolic consequences of basal hyperinsulinemia in alcoholic liver cirrhosis: relationship with postprandial changes in erythrocyte insulin-receptor affinity. Nutrition (1995) 1.40
Labelling pattern obtained by non-isotopic in situ hybridization as a prognostic factor in HPV-associated lesions. J Pathol (1996) 1.38
Sexual transmission during the incubation period of primary HIV infection. JAMA (2001) 1.37
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther (2010) 1.36
The relationship between crown size and ring width in Pinus sylvestris L. stems: dependence on indole-3-acetic acid, carbohydrates and nitrogen in the cambial region. Tree Physiol (1993) 1.35
Ignition and explosion risks of nanopowders. J Hazard Mater (2010) 1.34
Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS (1990) 1.33
Species- and stage-specific antigens in exoerythrocytic stages of Plasmodium falciparum. Am J Trop Med Hyg (1984) 1.30
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
The diagnosis of malaria infection using a solid-phase radioimmunoassay for the detection of malaria antigens. Application to the detection of Plasmodium berghei infection in mice. Parasitology (1980) 1.28
Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release (1998) 1.28
Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur Urol (2003) 1.27
Design of biodegradable particles for protein delivery. J Control Release (2002) 1.26
Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants. Eur J Pharm Biopharm (1998) 1.24
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol (2001) 1.22
Transmucosal macromolecular drug delivery. J Control Release (2005) 1.22
Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release (2001) 1.21
Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J Control Release (2006) 1.21
Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release (1998) 1.19
Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis (1998) 1.18
cAMP regulated membrane diffusion of a green fluorescent protein-aquaporin 2 chimera. Biophys J (2000) 1.18
Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res (1999) 1.18
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother (2000) 1.18
Low mercury concentrations cause oxidative stress and endothelial dysfunction in conductance and resistance arteries. Am J Physiol Heart Circ Physiol (2008) 1.18
High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr (1999) 1.17
Response of HIV RNA to didanosine as a predictive marker of survival. AIDS (1995) 1.15
Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. J Infect Dis (1999) 1.14
Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres. J Antimicrob Chemother (2001) 1.14
Coexistence of antigen-specific TH1 and TH2 cells in genetically susceptible BALB/c mice infected with Leishmania major. Immunobiology (1989) 1.14
Cellular localization of type 5 and type 6 ACs in collecting duct and regulation of cAMP synthesis. Am J Physiol Renal Physiol (2000) 1.11
Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore) (1992) 1.11
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS (2000) 1.10
Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J Control Release (1998) 1.08
Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res (1998) 1.08
Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxycillin-resin complexes for drug delivery to the gastric mucosa. Eur J Pharm Biopharm (2001) 1.08
Hepatitis C: a possible etiology for cryoglobulinaemia type II. Clin Exp Immunol (1992) 1.07
Surface activity and emulsification properties of hydrophobically modified dextrans. J Colloid Interface Sci (2002) 1.07
In vivo time course of synthesis and processing of major schizont membrane polypeptides in Plasmodium falciparum. Mol Biochem Parasitol (1986) 1.07
Atomic force microscopy study of the collagen fibre structure. Biol Cell (1994) 1.07
Localization and functional analysis of CHIP28k water channels in stably transfected Chinese hamster ovary cells. J Biol Chem (1993) 1.07
Cyclodextrins for drug delivery. J Drug Target (2010) 1.06
Skeletal muscle function and water permeability in aquaporin-4 deficient mice. Am J Physiol Cell Physiol (2000) 1.05
The Drosophila teashirt homeotic protein is a DNA-binding protein and modulo, a HOM-C regulated modifier of variegation, is a likely candidate for being a direct target gene. Mech Dev (1996) 1.05
Detection of human immunodeficiency virus type 1 (HIV-1) RNA in pools of sera negative for antibodies to HIV-1 and HIV-2. J Clin Microbiol (1998) 1.05
Evidence for the presence of aquaporin-3 in human red blood cells. J Biol Chem (1998) 1.03
Chronic destructive lung disease associated with a novel mycobacterium. Am J Respir Crit Care Med (1994) 1.03
Localization of the CHIP28 water channel in reabsorptive segments of the rat male reproductive tract. Eur J Cell Biol (1993) 1.03
Mutations in SDCCAG8/NPHP10 Cause Bardet-Biedl Syndrome and Are Associated with Penetrant Renal Disease and Absent Polydactyly. Mol Syndromol (2011) 1.03
Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. J Infect Dis (1996) 1.02
Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres. Int J Pharm (1999) 1.02
Growth-deficient mycobacteria in patients with AIDS: diagnosis by analysis of DNA amplified from blood or tissue. Clin Infect Dis (1995) 1.02
Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm (2001) 1.01
Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis (2000) 1.01
Preparation and characterization of protein C-loaded PLA nanoparticles. J Control Release (1999) 1.00
Development of a microencapsulated form of cefuroxime axetil using pH-sensitive acrylic polymers. J Microencapsul (1997) 1.00
Hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. J Control Release (2004) 0.99
Peritoneal cytology: impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus. Cancer Lett (2001) 0.99
Lidocaine-loaded biodegradable nanospheres. I. Optimization Of the drug incorporation into the polymer matrix. J Control Release (1999) 0.99